Lack of clinical benefit of improved angiographic results with sirolimus-eluting stents compared with paclitaxel and zotarolimus-eluting stents in patients with acute myocardial infarction undergoing percutaneous coronary intervention

Cheol Ung Choi, Seung-Woon Rha, Kang Yin Chen, Yong Jian Li, Kanhaiya L. Poddar, Zhe Jin, Yoshiyasu Minami, Soon Yong Suh, Jin Oh Na, Hong Euy Lim, Jin Won Kim, Eung Ju Kim, Chang Gyu Park, Hong Seog Seo, Dong Joo Oh

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Background: There is limited information regarding the angiographic and clinical outcomes among the different drug-eluting stents (DESs) in patients with acute myocardial infarction (AMI) undergoing percutaneous coronary intervention (PCI). Methods and Results: A total 355 consecutive AMI patients who underwent PCI with a sirolimus- (SES, n=116) or paclitaxel- (PES, n=153) or zotarolimus-eluting stent (ZES, n=86) were enrolled. The 6-month angiographic and 1-year clinical outcomes were compared among the 3 groups. At 6 months, there was a trend toward a higher incidence of binary restenosis in the PES group (SES: 8.6%, PES: 19.8%, ZES: 8.3%, P=0.052). Percentage of restenosis was higher in the PES group compared with SES, but was similar to ZES (SES: 18.75±18.16%, PES: 29.32±24.16%, ZES: 23.91±17.03%, P=0.006). Late loss was lower in the SES group compared with PES and ZES (SES: 0.44±0.52, PES: 0.83±0.87, ZES: 0.75±0.63, P<0.001). However, clinical outcomes, including mortality, MI, repeat PCI and major adverse cardiac events, were not different among the 3 groups. Conclusions: The angiographic benefit of SES did not translate into a clinical benefit for up to 1 year in AMI patients.

Original languageEnglish
Pages (from-to)2229-2235
Number of pages7
JournalCirculation Journal
Volume73
Issue number12
DOIs
Publication statusPublished - 2009 Dec 1

Fingerprint

Sirolimus
Percutaneous Coronary Intervention
Paclitaxel
Stents
Myocardial Infarction
Drug-Eluting Stents
Mortality
Incidence
zotarolimus

Keywords

  • Acute myocardial infarction
  • Paclitaxel-eluting stents
  • Sirolimus-eluting stents
  • Zotarolimus-eluting stents

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

@article{fdadbad73ebd420eb518be73ad78ca0c,
title = "Lack of clinical benefit of improved angiographic results with sirolimus-eluting stents compared with paclitaxel and zotarolimus-eluting stents in patients with acute myocardial infarction undergoing percutaneous coronary intervention",
abstract = "Background: There is limited information regarding the angiographic and clinical outcomes among the different drug-eluting stents (DESs) in patients with acute myocardial infarction (AMI) undergoing percutaneous coronary intervention (PCI). Methods and Results: A total 355 consecutive AMI patients who underwent PCI with a sirolimus- (SES, n=116) or paclitaxel- (PES, n=153) or zotarolimus-eluting stent (ZES, n=86) were enrolled. The 6-month angiographic and 1-year clinical outcomes were compared among the 3 groups. At 6 months, there was a trend toward a higher incidence of binary restenosis in the PES group (SES: 8.6{\%}, PES: 19.8{\%}, ZES: 8.3{\%}, P=0.052). Percentage of restenosis was higher in the PES group compared with SES, but was similar to ZES (SES: 18.75±18.16{\%}, PES: 29.32±24.16{\%}, ZES: 23.91±17.03{\%}, P=0.006). Late loss was lower in the SES group compared with PES and ZES (SES: 0.44±0.52, PES: 0.83±0.87, ZES: 0.75±0.63, P<0.001). However, clinical outcomes, including mortality, MI, repeat PCI and major adverse cardiac events, were not different among the 3 groups. Conclusions: The angiographic benefit of SES did not translate into a clinical benefit for up to 1 year in AMI patients.",
keywords = "Acute myocardial infarction, Paclitaxel-eluting stents, Sirolimus-eluting stents, Zotarolimus-eluting stents",
author = "Choi, {Cheol Ung} and Seung-Woon Rha and Chen, {Kang Yin} and Li, {Yong Jian} and Poddar, {Kanhaiya L.} and Zhe Jin and Yoshiyasu Minami and Suh, {Soon Yong} and Na, {Jin Oh} and Lim, {Hong Euy} and Kim, {Jin Won} and Kim, {Eung Ju} and Park, {Chang Gyu} and Seo, {Hong Seog} and Oh, {Dong Joo}",
year = "2009",
month = "12",
day = "1",
doi = "10.1253/circj.CJ-08-1086",
language = "English",
volume = "73",
pages = "2229--2235",
journal = "Circulation Journal",
issn = "1346-9843",
publisher = "Japanese Circulation Society",
number = "12",

}

TY - JOUR

T1 - Lack of clinical benefit of improved angiographic results with sirolimus-eluting stents compared with paclitaxel and zotarolimus-eluting stents in patients with acute myocardial infarction undergoing percutaneous coronary intervention

AU - Choi, Cheol Ung

AU - Rha, Seung-Woon

AU - Chen, Kang Yin

AU - Li, Yong Jian

AU - Poddar, Kanhaiya L.

AU - Jin, Zhe

AU - Minami, Yoshiyasu

AU - Suh, Soon Yong

AU - Na, Jin Oh

AU - Lim, Hong Euy

AU - Kim, Jin Won

AU - Kim, Eung Ju

AU - Park, Chang Gyu

AU - Seo, Hong Seog

AU - Oh, Dong Joo

PY - 2009/12/1

Y1 - 2009/12/1

N2 - Background: There is limited information regarding the angiographic and clinical outcomes among the different drug-eluting stents (DESs) in patients with acute myocardial infarction (AMI) undergoing percutaneous coronary intervention (PCI). Methods and Results: A total 355 consecutive AMI patients who underwent PCI with a sirolimus- (SES, n=116) or paclitaxel- (PES, n=153) or zotarolimus-eluting stent (ZES, n=86) were enrolled. The 6-month angiographic and 1-year clinical outcomes were compared among the 3 groups. At 6 months, there was a trend toward a higher incidence of binary restenosis in the PES group (SES: 8.6%, PES: 19.8%, ZES: 8.3%, P=0.052). Percentage of restenosis was higher in the PES group compared with SES, but was similar to ZES (SES: 18.75±18.16%, PES: 29.32±24.16%, ZES: 23.91±17.03%, P=0.006). Late loss was lower in the SES group compared with PES and ZES (SES: 0.44±0.52, PES: 0.83±0.87, ZES: 0.75±0.63, P<0.001). However, clinical outcomes, including mortality, MI, repeat PCI and major adverse cardiac events, were not different among the 3 groups. Conclusions: The angiographic benefit of SES did not translate into a clinical benefit for up to 1 year in AMI patients.

AB - Background: There is limited information regarding the angiographic and clinical outcomes among the different drug-eluting stents (DESs) in patients with acute myocardial infarction (AMI) undergoing percutaneous coronary intervention (PCI). Methods and Results: A total 355 consecutive AMI patients who underwent PCI with a sirolimus- (SES, n=116) or paclitaxel- (PES, n=153) or zotarolimus-eluting stent (ZES, n=86) were enrolled. The 6-month angiographic and 1-year clinical outcomes were compared among the 3 groups. At 6 months, there was a trend toward a higher incidence of binary restenosis in the PES group (SES: 8.6%, PES: 19.8%, ZES: 8.3%, P=0.052). Percentage of restenosis was higher in the PES group compared with SES, but was similar to ZES (SES: 18.75±18.16%, PES: 29.32±24.16%, ZES: 23.91±17.03%, P=0.006). Late loss was lower in the SES group compared with PES and ZES (SES: 0.44±0.52, PES: 0.83±0.87, ZES: 0.75±0.63, P<0.001). However, clinical outcomes, including mortality, MI, repeat PCI and major adverse cardiac events, were not different among the 3 groups. Conclusions: The angiographic benefit of SES did not translate into a clinical benefit for up to 1 year in AMI patients.

KW - Acute myocardial infarction

KW - Paclitaxel-eluting stents

KW - Sirolimus-eluting stents

KW - Zotarolimus-eluting stents

UR - http://www.scopus.com/inward/record.url?scp=73349098402&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=73349098402&partnerID=8YFLogxK

U2 - 10.1253/circj.CJ-08-1086

DO - 10.1253/circj.CJ-08-1086

M3 - Article

VL - 73

SP - 2229

EP - 2235

JO - Circulation Journal

JF - Circulation Journal

SN - 1346-9843

IS - 12

ER -